TBIO.jpg
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03 févr. 2021 16h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Announces Timing of Interim Results from mRNA Therapeutic Clinical Trial in Patients with Cystic Fibrosis; Data Expected in Early Q2 2021
07 janv. 2021 07h30 HE | Translate Bio, Inc.
-- MRT5005 is the first clinical-stage mRNA therapeutic with nebulized delivery to the lung and first to be administered in multiple doses for the treatment of a chronic genetic disease -- --...
TBIO.jpg
Translate Bio Announces Departure of Chief Financial Officer
22 déc. 2020 16h20 HE | Translate Bio, Inc.
LEXINGTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio to Participate in Upcoming Investor Conferences
12 nov. 2020 07h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Announces Third Quarter 2020 Financial Results and Reviews Recent Progress
05 nov. 2020 16h21 HE | Translate Bio, Inc.
-- Advances Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis (CF) with resumption of COVID-impacted enrollment and dosing -- -- Presented promising preclinical data at NACFC...
TBIO.jpg
Sanofi and Translate Bio mRNA COVID-19 Vaccine Candidate Induced High Antibody Levels in Preclinical Studies
15 oct. 2020 08h00 HE | Translate Bio, Inc.
-- mRNA-based vaccine candidate MRT5500 induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies -- -- Two doses of MRT5500 induced neutralizing antibody levels significantly...
TBIO.jpg
Translate Bio Highlights mRNA Platform Potential for the Treatment of Cystic Fibrosis (CF) at the 34th Annual North American Cystic Fibrosis Conference
07 oct. 2020 16h05 HE | Translate Bio, Inc.
-- Lead candidate MRT5005 leverages Translate Bio’s proprietary LNP and mRNA platform and is the only clinical-stage mRNA therapeutic in development for the treatment of CF -- -- Second CF program,...
TBIO.jpg
Translate Bio to Participate in Upcoming Investor Conferences
29 sept. 2020 16h05 HE | Translate Bio, Inc.
LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Resumes Enrollment and Dosing in Phase 1/2 Clinical Trial of MRT5005 in Cystic Fibrosis
08 sept. 2020 07h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio to Participate in Upcoming Investor Conferences
03 sept. 2020 07h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...